Gain Therapeutics Files 8-K
Ticker: GANX · Form: 8-K · Filed: Nov 28, 2025 · CIK: 1819411
| Field | Detail |
|---|---|
| Company | Gain Therapeutics, Inc. (GANX) |
| Form Type | 8-K |
| Filed Date | Nov 28, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $35,530,980.56, $14,469,019.44 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, 8-k
TL;DR
Gain Therapeutics filed an 8-K, but it's light on details. Watch for follow-up.
AI Summary
Gain Therapeutics, Inc. filed an 8-K on November 28, 2025, reporting other events and financial statements. The filing does not contain specific details about the nature of these events or the financial statements themselves.
Why It Matters
This filing indicates that Gain Therapeutics has made a regulatory submission, but the lack of specific details means its immediate impact on investors is unclear.
Risk Assessment
Risk Level: low — The filing is a standard procedural report with no disclosed material events or financial changes.
Key Players & Entities
- Gain Therapeutics, Inc. (company) — Registrant
- November 28, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 001-40237 (identifier) — Commission File Number
- 85-1726310 (identifier) — IRS Employer Identification No.
- 4800 Montgomery Lane , Suite 220 Bethesda , Maryland 20814 (address) — Address of principal executive offices
- ( 301 ) 500-1556 (phone_number) — Registrant's telephone number
FAQ
What specific 'Other Events' are being reported by Gain Therapeutics, Inc. in this 8-K filing?
The filing indicates 'Other Events' are being reported, but does not specify the nature of these events.
What is the purpose of the 'Financial Statements and Exhibits' section in this 8-K?
This section indicates that financial statements and exhibits are part of the filing, but their content is not detailed within the provided text.
When was the earliest event reported in this Form 8-K?
The earliest event reported is dated November 28, 2025.
Where is Gain Therapeutics, Inc. incorporated and what is its principal executive office address?
Gain Therapeutics, Inc. is incorporated in Delaware and its principal executive offices are located at 4800 Montgomery Lane, Suite 220, Bethesda, Maryland 20814.
What is the Commission File Number and IRS Employer Identification Number for Gain Therapeutics, Inc.?
The Commission File Number is 001-40237 and the IRS Employer Identification Number is 85-1726310.
Filing Stats: 725 words · 3 min read · ~2 pages · Grade level 10.5 · Accepted 2025-11-28 16:03:07
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value GANX The NASDAQ Stock Marke
- $35,530,980.56 — program for the offer and sale of up to $35,530,980.56 of the Company's common stock, par valu
- $14,469,019.44 — f, the Company has sold an aggregate of $14,469,019.44 of Common Stock pursuant to the Distrib
Filing Documents
- tm2530369d4_8k.htm (8-K) — 28KB
- tm2530369d4_ex5-1.htm (EX-5.1) — 9KB
- 0001104659-25-116947.txt ( ) — 204KB
- ganx-20251128.xsd (EX-101.SCH) — 3KB
- ganx-20251128_lab.xml (EX-101.LAB) — 33KB
- ganx-20251128_pre.xml (EX-101.PRE) — 22KB
- tm2530369d4_8k_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. On November 28, 2025, Gain Therapeutics, Inc. (the "Company"), filed a prospectus supplement (the "Prospectus Supplement") with the U.S. Securities and Exchange Commission (the "SEC") in connection with the Company's "at the market offering" program for the offer and sale of up to $35,530,980.56 of the Company's common stock, par value $0.0001 per share (the "Common Stock"), from time to time through Oppenheimer & Co. Inc. ("Oppenheimer"), as sales agent, pursuant to the Company's existing Equity Distribution Agreement (the "Distribution Agreement"), dated September 6, 2024. As of the date hereof, the Company has sold an aggregate of $14,469,019.44 of Common Stock pursuant to the Distribution Agreement and the related prospectus supplement, dated September 6, 2024 to the Company's Registration Statement on Form S-3 (File No. 333-265061). The offer and sale of additional Common Stock by the Company under the Distribution Agreement will be made pursuant to the Prospectus Supplement, dated November 28, 2025, and the accompanying base prospectus, dated November 26, 2025, contained therein, which together form a part of the Company's shelf registration statement on Form S-3 (File No. 333-287622), initially filed with the SEC on May 28, 2025 and which became effective on November 26, 2025 (the "Registration Statement"). Lowenstein Sandler LLP, counsel to the Company, has issued a legal opinion relating to the validity of the $35,530,980.56 of Common Stock that may be offered and sold pursuant to the Distribution Agreement and related Prospectus Supplement. A copy of such legal opinion, including the consent included therein, is attached as Exhibit 5.1 to this Current Report on Form 8-K. This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the Common Shares discussed herein, nor shall there be any sale of such securities in any state or jurisdiction in which such offer, solicitation or sa
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits The exhibits listed below are furnished as part of this Current Report on Form 8-K. Exhibit No. Description 5.1 Opinion of Lowenstein Sandler LLP. 23.1 Consent of Lowenstein Sandler LLP (contained in Exhibit 5.1). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GAIN THERAPEUTICS, INC. Date: November 28, 2025 By: /s/ Gene Mack Name: Gene Mack Title: Chief Executive Officer